according to the information provided by the enterprise investigation, Henan xinsifang pharmaceutical co., ltd. is currently in business. Therefore, it is a company that is allowed to operate by law, so it is formal.

Henan xinsifang pharmaceutical co., ltd. was established in 1953 with a registered capital of 2 million yuan, engaged in the production and marketing of traditional Chinese medicine and health care products. Located in Zhoukou City, which is known as "Nanpidu", the company is one of the important enterprises in Sifang Pharmaceutical Enterprise Group of Henan Province. It is a designated manufacturer of Chinese patent medicines in Henan Province, one of the top ten enterprises in Chinese medicine industry in Henan Province, one of the top 5 pharmaceutical industrial enterprises in China, and the largest production base of blood-enriching drugs in China. The newly-built new Sifang new industrial park covers an area of more than 2 mu, with advanced production technology, production equipment and gmp standard workshops, total assets of 16 million, and 68 employees, including 15 senior titles, 71 intermediate titles and 318 technicians. The company always adheres to the business philosophy of "serving the public in all directions and creating a healthy life". At present, there are more than 8 varieties in seven dosage forms, and the main products are new Sifang brand Ejiao Buxue ointment, Ejiao Buxue oral liquid, Xiaoke Tongmai oral liquid and compound platycodon grandiflorum Zhike tablets. New national products such as Qianlietong Capsule, Xiaoaiping Oral Liquid, Gujin Pill and Changweining Tablet have been introduced. The product structure is reasonable, and some products are exported to Southeast Asian countries and regions. Ejiao Buxue Ointment ranks in the top of single product sales in the current domestic blood-enriching market. The series of products led by Ejiao Buxue Ointment have won provincial, ministerial and national gold medals "Baokang" and "Chengda" for 15 times, and have been rated as selected trademarks by the State Administration for Industry and Commerce. In recent years, the company has extensively integrated the superior resources of social science and technology, combined with Industry-University-Research, and has successively established close technical cooperation relations with nearly 5 scientists from six domestic first-class universities in Shanghai and Beijing, and has its own independent scientific research institutions to promote the industrialization of various technological achievements. The newly developed new drug "Xiaoke Tongmai Oral Liquid" will soon become a new economic growth point for the company. In the situation of fierce competition in the pharmaceutical market, the company puts forward a long-term development strategic plan around the development opportunity of "second venture". Based on the principle of high-level design, high starting point and largest scale, we have invested in the construction of 3 million boxes of Xiaoke Tongmai oral liquid production line and the modernization and expansion project of traditional Chinese medicine. It has created a good development platform for the company. The project can produce 1 billion tablets, 5 tons of granules, 3 million capsules, 1 million oral liquids and 5 million bottles of decoctions, all of which quadruple the current output. The company is moving towards an international, standardized and modern large-scale pharmaceutical enterprise. New Sifang Pharmaceutical will create the glory of modern Chinese medicine with the glory of pharmaceutical industry for a hundred years.